[1]刘亚,庞亚梅,李宏,等.磷酸肌醇3激酶调节亚基1、紧密连接蛋白4和有丝分裂基因A相关激酶2在非小细胞肺癌患者中的联合诊断价值[J].陕西医学杂志,2026,(7):980-985.[doi:DOI:10.3969/j.issn.1000-7377.2026.07.019]
　LIU Ya,PANG Yamei,LI Hong,et al.Combined diagnostic value of phosphoinositide-3-kinase regulatory subunit 1,CLAUDIN-4 and never in mitosis gene A -related kinase 2 in patients with non-small cell lung cancer[J].,2026,(7):980-985.[doi:DOI:10.3969/j.issn.1000-7377.2026.07.019]
点击复制

磷酸肌醇3激酶调节亚基1、紧密连接蛋白4和有丝分裂基因A相关激酶2在非小细胞肺癌患者中的联合诊断价值

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年7期
页码:
980-985
栏目:
临床病理
出版日期:
2026-07-05

文章信息/Info

Title:
Combined diagnostic value of phosphoinositide-3-kinase regulatory subunit 1,CLAUDIN-4 and never in mitosis gene A -related kinase 2 in patients with non-small cell lung cancer
作者:
刘亚; 庞亚梅; 李宏; 阳甜; 宁谦; 任徽
(西安交通大学第一附属医院呼吸与危重症医学科,陕西 西安710061)
Author(s):
LIU Ya; PANG Yamei; LI Hong; YANG Tian; NING Qian; REN Hui
(Department of Respiratory and Critical Care Medicine,First Affiliated Hospital of Xi’an JiaoTong University,Xi’an 710061,China)
关键词:
非小细胞肺癌; 磷酸肌醇3激酶调节亚基1/p85α; 有丝分裂基因A; 紧密连接蛋白4; 诊断; 危险因素
Keywords:
NSCLC; PIK3R1/p85α; NEK2; CLAUDIN-4; Diagnosis; Risk factors
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2026.07.019
文献标志码:
A
摘要:
目的：探讨磷酸肌醇3激酶调节亚基1（PIK3R1）、紧密连接蛋白4（CLAUDIN-4）和有丝分裂基因A（NIMA）相关激酶2（NEK2）在非小细胞肺癌（NSCLC）患者肿瘤组织中的表达水平及其诊断价值。方法：回顾性选取手术治疗的340例NSCLC患者为研究对象。分别采用RT-qPCR和Western blotting检测NSCLC组织与癌旁组织（距离肿瘤>3 cm）中PIK3R1/p85α、CLAUDIN-4和NEK2的mRNA和蛋白表达水平；卡方检验评估PIK3R1/p85α、CLAUDIN-4和NEK2蛋白水平与NSCLC患者临床病理特征的关系。此外，采用Pearson分析NSCLC患者肿瘤组织中PIK3R1/p85α、CLAUDIN-4和NEK2蛋白水平的相关性；采用受试者工作特征（ROC）曲线评估PIK3R1/p85α、CLAUDIN-4和NEK2水平对NSCLC的诊断效能。多因素Cox回归模型分析影响NSCLC患者预后的因素。结果：与癌旁组织比较，NSCLC患者肿瘤组织中PIK3R1的mRNA和蛋白水平显著降低，CLAUDIN-4和NEK2的mRNA和蛋白水平显著升高，差异具有统计学意义（均P<0.01）。此外，临床和病理参数的相关性分析显示，PIK3R1/p85α蛋白表达与NSCLC患者年龄、性别和病理类型无相关性（均P>0.05），与患者的肿瘤大小、临床分期、病理学分化、淋巴结转移和5年生存率呈显著负相关（均P<0.05）；CLAUDIN-4蛋白表达与NSCLC患者年龄、性别和病理类型无相关性，与患者的肿瘤大小、临床分期、病理学分化、淋巴结转移和5年生存率显著正相关（均P<0.05）；NEK2蛋白表达与NSCLC患者的肿瘤大小、病理类型、临床分期、病理学分化、淋巴结转移和5年生存率显著正相关（均P<0.05）。与此同时，PIK3R1/p85α、CLAUDIN-4和NEK2联合诊断NSCLC的曲线下面积（AUC）为0.995，敏感性为95%，特异性为100%，95%CI为0.988~1.000。Cox模型对NSCLC预后多因素生存分析结果显示PIK3R1/p85α、CLAUDIN-4和NEK2是NSCLC患者预后的独立危险因素，肿瘤大小、TNM分期、病理分级、淋巴结转移均是非独立危险因素。结论：PIK3R1/p85α、CLAUDIN-4和NEK2联合检测对NSCLC具有较高的诊断效能，值得临床推广应用。
Abstract:
Objective:To investigate the expression levels of Phosphoinositide-3-Kinase Regulatory Subunit 1 (PIK3R1),CLAUDIN-4 and Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) in tumor tissues of non-small-cell lung carcinoma (NSCLC) patients and their diagnostic value.Methods：A retrospective study selected 340 patients with NSCLC who underwent surgery as the research objects.The mRNA and protein levels of PIK3R1/p85α,CLAUDIN-4 and NEK2 in NSCLC tissues and adjacent normal tissues (>3 cm away from the tumor) were detected with RT-qPCR and Western blotting;and the relationship between the protein levels of PIK3R1/p85α,CLAUDIN-4 and NEK2 and the clinical and pathological characteristics of NSCLC patients were analyzed by Chi square test.Furthermore,Pearson analysis was used to evaluate the correlation of PIK3R1/p85α,CLAUDIN-4 and NEK2 protein levels in tumor tissues of NSCLC patients,and the receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of PIK3R1/p85α,CLAUDIN-4 and NEK2 levels in NSCLC.Multivariate survival analysis of NSCLC patients was performed using Cox model.Results:Compared with adjacent normal tissues,the mRNA and protein levels of PIK3R1/p85α in tumor tissues from NSCLC patients were significantly decreased,while CLAUDIN-4 and NEK2 mRNA and protein levels were significantly increased,with statistically significant differences (all P<0.01).Moreover,correlation analysis of clinical and pathological parameters showed that PIK3R1/p85α protein level was not correlated with age,gender,and pathological type of NSCLC patients (all P>0.05),but was significantly negatively correlated with tumor size,clinical stage,pathological differentiation,lymph node metastasis,and 5-year survival rate (all P<0.05);CLAUDIN-4 protein level was not correlated with age,gender,and pathological type of NSCLC patients,but was significantly positively correlated with tumor size,clinical stage,pathological differentiation,lymph node metastasis,and 5-year survival rate (all P<0.05);NEK2 protein level was significantly positively correlated with pathological type,tumor size,clinical stage,pathological differentiation,lymph node metastasis,and 5-year survival rate (all P<0.05).Meanwhile,the area under the curve (AUC) of PIK3R1/p85α,CLAUDIN-4 and NEK2 in the diagnosis of NSCLC was 0.995,the sensitivity was 95%,the specificity was 100%,and the 95%CI was 0.988~1.000.Multivariate survival analysis of the prognosis of NSCLC by Cox model showed that the protein levels of PIK3R1/p85α,CLAUDIN-4 and NEK2 were independent risk factors affecting the prognosis,while tumor size,TNM stage,pathological grade and lymph node metastasis were non independent risk factors.Conclusion:The combined detection of PIK3R1/p85α,CLAUDIN-4 and NEK2 levels has a high diagnostic efficacy for NSCLC,which is worthy of clinical application.

参考文献/References:

[1]JEON H,WANG S,SONG J,et al.Update 2025：Management of non-small-cell lung cancer[J].Lung,2025,203(1)：53.
[2]KWAK S H,KIM C Y,LEE S H,et al.Updates on lung cancer screening for early detection[J].Korean J Intern Med,2025,40(4)：546-556.
[3]DENNEHY C,CONROY M R,FORDE P M.Immunotherapy for resectable lung cancer[J].Cancer,2025,131(10)：e35849.
[4]焦健方,张佳.早期非小细胞肺癌经PD-1抑制剂与立体定向体部放疗联合治疗的疗效观察研究[J].陕西医学杂志,2026,55(1)：48-52.
[5]XIE H,LI Y,LI X.Cancer-associated PIK3R1 genetic aberrations and precision medicine[J].Int J Med Sci,2025,22(12)：2932-2943.
[6]谈洪蕾,刘珊,李晓梅,等.口腔鳞癌患者血清miRNA-503-5p、PIK3R1表达水平与临床特征及预后的相关性研究[J].临床和实验医学杂志,2024,23(14)：1546-1550.
[7]徐培,陶冶,刘安东,等.Cyfra21-1、PIK3R1、PD-L1表达水平变化与口腔癌患者预后的相关性分析[J].赤峰学院学报(自然科学版),2025,41(8)：25-29.
[8]陈港军.基于生物信息学数据库探究PIK3R1对肺腺癌预后的影响 [D];广东：暨南大学,2023.
[9]KUTLU ,GNEN D,AYAZ D,et al.CLAUDIN-4 overexpression predicts poor survival and platinum resistance in epithelial ovarian cancer：A potential biomarker for clinical decision-making[J].Diagnostics (Basel),2025,15(24)：3163.
[10]张明慧,赵长燕,贺红梅.三阴性乳腺癌组织中CLAUDIN-4、p53、Ki-67表达与病理特征及预后的相关性[J].临床和实验医学杂志,2025,24(11)：1178-1182.
[11]胡俊彪,张春霆,吴慧玲.前列腺癌中CLAUDIN-4和MMP-9表达及其临床意义[J].浙江临床医学,2024,26(6)：823-825.
[12]王勇,庞青,满忠然,等.CLAUDIN-4在胆囊癌中的表达及与临床病理特征、预后的关系[J].牡丹江医学院学报,2021,42(2)：30-33，45.
[13]ABDELRAHMAN A E,ELBADRY F A,IBRAHIM T R,et al.Role of HEG1 and CLAUDIN-4 immunohistochemistry in the differential diagnosis of lung adenocarcinoma from malignant mesothelioma in pleural effusion cytology[J].Turk Patoloji Derg,2025,41(2)：42-50.
[14]GRECU D F,ZORIL M V,STANCA L,et al.Immunoexpression of CLAUDIN-4 in non-small cell lung carcinomas[J].Curr Health Sci J,2024,50(5)：508-514.
[15]NASO J R,CHURG A.CLAUDIN-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4[J].Hum Pathol,2020,100：10-14.
[16]李峰,王布,徐凯伦,等.非小细胞肺癌组织NEK2、EPHA5表达与临床病理特征、EGFR突变和预后的关系[J].现代生物医学进展,2024,24(12)：2396-2400.
[17]李青,王若涵,张丽,等.非小细胞肺癌癌组织和癌旁组织中NEK2、PHF5A表达水平变化及其临床意义[J].国际检验医学杂志,2025,46(9)：1148-1152.
[18]中华医学会肿瘤学分会.中华医学会肺癌临床诊疗指南(2025版)[J].中华肿瘤杂志,2025,47(9)：769-810.
[19]MEYER M L,FITZGERALD B G,PAZ-ARES L,et al.New promises and challenges in the treatment of advanced non-small-cell lung cancer[J].Lancet,2024,404(10454)：803-822.
[20]GUPTA I,GAYKALOVA D A.Unveiling the role of PIK3R1 in cancer：A comprehensive review of regulatory signaling and therapeutic implications[J].Semin Cancer Biol,2024,106-107：58-86.
[21]KATOH M,KATOH M.Claudin 1,4,6 and 18 isoform 2 as targets for the treatment of cancer (Review)[J].Int J Mol Med,2024,54(5)：100.
[22]FUJIWARA-TANI R,MORI S,OGATA R,et al.CLAUDIN-4：A new molecular target for epithelial cancer therapy[J].Int J Mol Sci,2023,24(6)：5494.
[23]UTHAYANAN L,EL-BAHRAWY M.Potential roles of claudin-3 and CLAUDIN-4 in ovarian cancer management[J].J Egypt Natl Canc Inst,2022,34(1)：24.
[24]CHAI J,LIU X,HU X,et al.Correlation analysis of circulating tumor cells and CLAUDIN-4 in breast cancer[J].Pathol Oncol Res,2023,29：1611224.
[25]ZHANG X,WANG X,WEN Y,et al.Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer[J].Clin Transl Med,2024,14(4)：e1649.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(7):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(7):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(7):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(7):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(7):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(7):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

备注/Memo

备注/Memo:
陕西省重点研发计划项目（2022SF-426）
更新日期/Last Update: 2026-07-10